All Stories

  1. Immune Interest of a rhenium-selenium compound

    Article • Current Pharmaceutical Design, August 2023, Bentham Science Publishers

    DIDIER DESMAELE, Philippe Collery

  2. Design of Rhenium Compounds in Targeted Anticancer Therapeutics

    Article • Current Pharmaceutical Design, November 2019, Bentham Science Publishers

    Philippe Collery

  3. The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers

    Article • Investigational New Drugs, January 2019, Springer Science + Business Media

    Philippe Collery